Ozen Ozkan, Gunaydin Mucahit, Tosun Aptekin, Coskun Zafer Unsal, Aytekin Kursad, Takir Selcuk
Ozkan Ozen, MD. Assistant Professor, Department of Radiology, Alanya Alaaddin Keykubat University, Antalya, Turkey. Faculty of Medicine, Debboy District, Giresun University, Giresun, Turkey.
Mucahit Gunaydin, MD. Assistant Professor, Department of Emergency Medicine, Faculty of Medicine, Debboy District, Giresun University, Giresun, Turkey.
Pak J Med Sci. 2019 Jul-Aug;35(4):1132-1137. doi: 10.12669/pjms.35.4.313.
Medications are generally administered by either the enteric or parenteral route. With parenteral administration, intramuscular (IM) is the preferred approach because it increases the bioavailability of the drug, acts more quickly than the enteric route. The aim of this study was to determine the rate of true dorsogluteal intramuscular drug injection and to determine the causes for application failures in practice by ultrasonography (US).
The study was conducted from May 1 to May 30, 2017 in Giresun University Education and Research Hospital, Giresun, Turkey. We examined 60 patients who were administered dorsogluteal IM injection with a 38.1mm length needle. After the injection, localization of medications (whether intramuscular or subcutaneous adipose tissue [SAT]) was evaluated by Ultrasound.
Female/male ratio of the patients was 27/33, with a mean age of 39.78±2.16 years. Obese/normal weight ratio was 20/40. The mean dorsogluteal area SAT thickness of obese and normal weight patients were 32.34±2.17 mm and 20.85±1.20 mm, respectively. In 23 of the patients, IM injected drug was observed in the SAT, while it was observed in the IM area in 37 patients. Medication was observed in IM area in 37 of 50 patients who dorsogluteal region SAT thickness was appropriate (SAT thickness lower than 33.1mm) for IM injection while it was seen in SAT area in 13 patients.
SAT thickness values are important if IM drug injection is to be administered correctly. Unsuccessful IM injections may be seen even in patients with appropriate SAT thicknesses.
药物通常通过肠内或胃肠外途径给药。在胃肠外给药中，肌内注射（IM）是首选方法，因为它能提高药物的生物利用度，起效比肠内途径更快。本研究的目的是通过超声检查（US）确定真正的臀大肌肌内药物注射率，并确定实际应用失败的原因。
该研究于2017年5月1日至5月30日在土耳其吉雷松市吉雷松大学教育与研究医院进行。我们检查了60例接受38.1毫米长针头臀大肌肌内注射的患者。注射后，通过超声评估药物的定位（无论是在肌肉内还是皮下脂肪组织[SAT]中）。
患者的男女比例为27/33，平均年龄为39.78±2.16岁。肥胖/正常体重比例为20/40。肥胖和正常体重患者的平均臀大肌区域SAT厚度分别为32.34±2.17毫米和20.85±1.20毫米。在23例患者中，在SAT中观察到肌内注射的药物，而在37例患者的肌肉区域中观察到药物。在50例臀大肌区域SAT厚度适合肌内注射（SAT厚度低于33.1毫米）的患者中，37例在肌肉区域观察到药物，13例在SAT区域观察到药物。
如果要正确进行肌内药物注射，SAT厚度值很重要。即使在SAT厚度合适的患者中也可能出现肌内注射失败的情况。
